Advertisement

Annular bullous diseases

      Abstract

      Annular bullous dermatoses represent an etiologically diverse group of cutaneous phenomena that present with a figurate morphology in association with vesicles and bullae. This group of diverse conditions consists of bullous pemphigoid; pemphigoid gestationis; epidermolysis bullosa simplex, Dowling-Meara type; linear immunoglobulin A bullous dermatosis; chronic bullous disease of childhood; anti-p200 pemphigoid; subcorneal pustular dermatosis; and immunoglobulin A pemphigus. Astute examination of clinical, histopathologic, and serologic features is crucial in distinguishing these bullous dermatoses. We review the clinical presentation, pathophysiology, histopathology, and treatments for each bullous annular disease to aid physicians in their recognition, diagnosis, and management.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kridin K.
        Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.
        Immunol Res. 2018; 66: 6-17
        • Watts PJ
        • Khachemoune A.
        subcorneal pustular dermatosis: a review of 30 years of progress.
        Am J Clin Dermatol. 2016; 17: 653-671
        • Tsuruta D
        • Ishii N
        • Hamada T
        • et al.
        IgA pemphigus.
        Clin Dermatol. 2011; 29: 437-442
        • Sami N
        Autoimmune Bullous Diseases.
        Springer International Publishing, Cham, Switzerland2016
        • Miyamoto D
        • Santi CG
        • Aoki V
        • pemphigoid Maruta CW.Bullous
        An Bras Dermatol. 2019; 94: 133-146
        • Kridin K
        • Ludwig RJ.
        The growing incidence of bullous pemphigoid: overview and potential explanations.
        Front Med (Lausanne). 2018; 5: 220
        • Esmaili N
        • Mortazavi H
        • Chams-Davatchi C
        • et al.
        Association between HLA-DQB1*03:01 and bullous pemphigoid in Iranian patients.
        Iran J Immunol. 2013; 10: 1-9
        • Okazaki A
        • Miyagawa S
        • Yamashina Y
        • Kitamura W
        • Shirai T.
        Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid.
        J Dermatol. 2000; 27: 149-156
        • Cozzani E
        • Gasparini G
        • Burlando M
        • Drago F
        • Parodi A.
        Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects.
        Autoimmun Rev. 2015; 14: 438-445
        • Verheyden MJ
        • Bilgic A
        • Murrell DF.
        A systematic review of drug-induced pemphigoid.
        Acta Derm Venereol. 2020; 100: adv00224
        • Skandalis K
        • Spirova M
        • Gaitanis G
        • Tsartsarakis A
        • Bassukas ID.
        Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
        J Eur Acad Dermatol Venereol. 2012; 26: 249-253
        • Huilaja L
        • Mäkikallio K
        • Tasanen K.
        Gestational pemphigoid.
        Orphanet J Rare Dis. 2014; 9: 136
        • Cobo MF
        • Santi CG
        • Maruta CW
        • Aoki V.
        Pemphigoid gestationis: clinical and laboratory evaluation.
        Clinics (Sao Paulo). 2009; 64: 1043-1047
        • Di Zenzo G
        • Calabresi V
        • Grosso F
        • Caproni M
        • Ruffelli M
        • Zambruno G.
        The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies.
        J Invest Dermatol. 2007; 127: 864-873
        • Marks JG
        • Miller JJ.
        Lookingbill and Marks’ Principles of Dermatology.
        5th ed. Elsevier, New York, NY2006
        • Henry S.
        Recognizing presentations of pemphigoid gestationis: a case study.
        Case Rep Obstet Gynecol. 2014; 2014415163
        • Powell AM
        • Sakuma-Oyama Y
        • Oyama N
        • et al.
        Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy.
        Arch Dermatol. 2005; 141: 705-710
        • Thoma-Uszynski S
        • Uter W
        • Schwietzke S
        • et al.
        BP230- and BP180-specific auto-antibodies in bullous pemphigoid.
        J Invest Dermatol. 2004; 122: 1413-1422
        • Feng S
        • Wu Q
        • Jin P
        • et al.
        Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
        Int J Dermatol. 2008; 47: 225-228
        • Aoyama Y
        • Asai K
        • Hioki K
        • Funato M
        • Kondo N
        • Kitajima Y.
        Herpes gestationis in a mother and newborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain.
        Arch Dermatol. 2007; 143: 1168-1172
        • De A
        • Rao R
        • Balachandran C.
        Salt split technique: a useful tool in the diagnosis of subepidermal bullous disorders.
        Indian J Dermatol. 2010; 55: 334-336
        • Kridin K
        • Shihade W
        • Bergman R.
        Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis.
        Acta Derm Venereol. 2019; 99: 72-77
        • Lipozenčić J
        • Ljubojevic S
        • Bukvić-Mokos Z.
        Pemphigoid gestationis.
        Clin Dermatol. 2012; 30: 51-55
        • Fontaine J
        • Joly P
        • Roujeau JC.
        Treatment of bullous pemphigoid.
        J Dermatol. 2003; 30: 83-90
        • Horn HM
        • Tidman MJ.
        The clinical spectrum of epidermolysis bullosa simplex.
        Br J Dermatol. 2000; 142: 468-472
        • Lattouf C
        • Schachner L.
        Epidermolysis bullosa simplex, Dowling-Meara type with eruptive nevi.
        Int J Dermatol. 2012; 51: 1094-1096
        • Wagner M
        • Hintner H
        • Bauer JW
        • Onder K.
        Gene expression analysis of an epidermolysis bullosa simplex Dowling-Meara cell line by subtractive hybridization: recapitulation of cellular differentiation, migration and wound healing.
        Exp Dermatol. 2012; 21: 111-117
        • Boeira VL
        • Souza ES
        • Rocha Bde O
        • et al.
        Inherited epidermolysis bullosa: clinical and therapeutic aspects.
        An Bras Dermatol. 2013; 88: 185-198
        • Bergman R
        • Harel A
        • Sprecher E.
        Dyskeratosis as a histologic feature in epidermolysis bullosa simplex-Dowling Meara.
        J Am Acad Dermatol. 2007; 57: 463-466
        • Montaudié H
        • Chiaverini C
        • Sbidian E
        • Charlesworth A
        • Lacour JP.
        Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases.
        Orphanet J Rare Dis. 2016; 11: 117
        • Lammer J
        • Hein R
        • Roenneberg S
        • Biedermann T
        • Volz T.
        Drug-induced linear IgA bullous dermatosis: a case report and review of the literature.
        Acta Derm Venereol. 2019; 99: 508-515
        • Garel B
        • Ingen-Housz-Oro S
        • Afriat D
        • et al.
        Drug-induced linear immunoglobulin A bullous dermatosis: a French retrospective pharmacovigilance study of 69 cases.
        Br J Clin Pharmacol. 2019; 85: 570-579
        • Humphrey VS
        • Lee JJ
        • Supakorndej T
        • Malik SM
        • Huen AC
        • Jaroslaw J.
        Linear IgA bullous dermatosis preceding the diagnosis of primary sclerosing cholangitis and ulcerative colitis: a case report.
        Am J Dermatopathol. 2019; 41: 498-501
        • Valle Del Barrio B
        • Luraschi D
        • Micheletti R
        • Hiffler L
        • Arias AP.
        Bullous dermatosis suspected in an 8-month-old child in Guinea-Bissau.
        Oxf Med Case Reports. 2019; 2019: omz004
        • Visentainer L
        • Massuda JY
        • Cintra ML
        • Magalhães RF.
        Vancomycin-induced linear IgA bullous dermatosis (LABD)-an atypical presentation.
        Clin Case Rep. 2019; 7: 1091-1093
        • Bernett CN
        • Fong M
        • Yadlapati S
        • Rosario-Collazo JA.
        LinearIGA Dermatosis.
        StatPearls Publishing, Treasure Island, FL2020
        • Díaz MS
        • Morita L
        • Ferrari B
        • et al.
        Linear IgA bullous dermatosis: a series of 17 cases.
        Actas Dermosifiliogr (Engl Ed). 2019; 110: 673-680
        • Sarikaya Solak S
        • Ficicioglu S
        Cephalosporin-induced linear IgA dermatosis in a child: case report and literature review.
        Dermatol Ther. 2019; 32: e12927
        • Commin MH
        • Schmidt E
        • Duvert-Lehembre S
        • et al.
        Clinical and immunological features and outcome of anti-p200 pemphigoid.
        Br J Dermatol. 2016; 175: 776-781
        • Chanal J
        • Ingen-Housz-Oro S
        • Ortonne N
        • et al.
        Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms.
        Br J Dermatol. 2013; 169: 1041-1048
        • Genovese G
        • Venegoni L
        • Fanoni D
        • Muratori S
        • Berti E
        • Marzano AV.
        Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients.
        Orphanet J Rare Dis. 2019; 14: 115
        • Polat M
        • Lenk N
        • Kürekçi E
        • Oztaş P
        • Artüz F
        • Alli N
        Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug.
        Am J Clin Dermatol. 2007; 8: 389-391
        • Cozzani E
        • Di Zenzo G
        • Gasparini G
        • et al.
        Autoantibody profile of a cohort of 54 Italian patients with linear IgA bullous dermatosis: LAD-1 denoted as a major auto-antigen of the lamina lucida subtype.
        Acta Derm Venereol. 2020; 100: adv00070
        • Bolognia JL
        • Schaffer JV
        • Cerroni L
        Dermatology. 4th ed. Elsevier, Philadelphia, PA2018
        • Guide SV
        • Marinkovich MP.
        Linear IgA bullous dermatosis.
        Clin Dermatol. 2001; 19: 719-727
        • Gottlieb J
        • Ingen-Housz-Oro S
        • Alexandre M
        • et al.
        Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.
        Br J Dermatol. 2017; 177: 212-222
        • Kridin K
        • Ahmed AR.
        Anti-p200 Pemphigoid: a systematic review.
        Front Immunol. 2019; 10: 2466
        • Vafia K
        • Groth S
        • Beckmann T
        • et al.
        Pathogenicity of autoantibodies in anti-p200 pemphigoid.
        PLoS One. 2012; 7: e41769
        • Meijer JM
        • Diercks GF
        • Schmidt E
        • Pas HH
        • Jonkman MF.
        Laboratory diagnosis and clinical profile of anti-p200 pemphigoid.
        JAMA Dermatol. 2016; 152: 897-904
        • Lau I
        • Goletz S
        • Holtsche MM
        • Zillikens D
        • Fechner K
        • Schmidt E.
        Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin.
        J Am Acad Dermatol. 2019; 81: 1195-1197
        • Goletz S
        • Hashimoto T
        • Zillikens D
        • Schmidt E.
        Anti-p200 pemphigoid.
        J Am Acad Dermatol. 2014; 71: 185-191
        • Egan CA
        • Yee C
        • Zillikens D
        • Yancey KB.
        Anti-p200 pemphigoid: diagnosis and treatment of a case presenting as an inflammatory subepidermal blistering disease.
        J Am Acad Dermatol. 2002; 46: 786-789
        • Hegazy S
        • Bouchouicha S
        • Khaled A
        • Laadher L
        • Sellami MK
        • Zeglaoui F.
        IgA pemphigus showing IgA antibodies to desmoglein 1 and 3.
        Dermatol Pract Concept. 2016; 6: 31-33
        • Ohata C
        • Ishii N
        • Koga H
        • et al.
        Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: a series of 145 cases.
        J Am Acad Dermatol. 2015; 73: 50-55
        • Bordignon M
        • Zattra E
        • Montesco MC
        • Alaibac M.
        Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) with absence of desmoglein 1 and 3 antibodies: case report and literature review.
        Am J Clin Dermatol. 2008; 9: 51-55
        • Hashimoto T.
        Immunopathology of IgA pemphigus.
        Clin Dermatol. 2001; 19: 683-689
        • Feldmeyer L
        • Hashimoto T
        • Borradori L.
        Superficial neutrophilic dermatoses: from subcorneal pustular dermatosis (Sneddon-Wilkinson Disease) to intercellular IgA dermatoses.
        in: Wallach D Vignon-Pennamen MD Valerio Marzano A Neutrophilic Dermatoses. Springer International Publishing, Cham, Switzerland2018: 101-117
        • Owczarczyk-Saczonek A
        • Znajewska-Pander A
        • Owczarek W
        • Maciejewska-Radomska A
        • Placek W.
        Clinicopathologic retrospective analysis of annular pustular psoriasis.
        Acta Dermatovenerol Alp Pannonica Adriat. 2018; 27: 215-219
        • Liao PB
        • Rubinson R
        • Howard R
        • Sanchez G
        • Frieden IJ.
        Annular pustular psoriasis–most common form of pustular psoriasis in children: report of three cases and review of the literature.
        Pediatr Dermatol. 2002; 19: 19-25
        • Vocks E
        • Worret WI
        • Ring J.
        Erythema annulare centrifugum-type psoriasis: a particular variant of acute-eruptive psoriasis.
        J Eur Acad Dermatol Venereol. 2003; 17: 446-448
        • Neri I
        • Piraccini BM
        • Guareschi E
        • Patrizi A.
        Bullous tinea pedis in two children.
        Mycoses. 2004; 47: 475-478
      1. Centers for Disease Control and Prevention. Hygiene-related diseases: athlete's foot (tinea pedis). Available at: https://www.cdc.gov/healthywater/hygiene/disease/athletes_foot.html. Accessed: December 14, 2020.

        • Szatkowski J
        • Schwartz RA.
        Acute generalized exanthematous pustulosis (AGEP): a review and update.
        J Am Acad Dermatol. 2015; 73: 843-848
        • Sidoroff A
        • Halevy S
        • Bavinck JN
        • Vaillant L
        • Roujeau JC.
        Acute generalized exanthematous pustulosis (AGEP)—a clinical reaction pattern.
        J Cutan Pathol. 2001; 28: 113-119